Article

Oligemic Hypoperfusion Differentially Affects Tau and Amyloid-β

Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 3212 Biological Sciences III, Irvine, CA 92697-4545, USA.
American Journal Of Pathology (Impact Factor: 4.59). 07/2010; 177(1):300-10. DOI: 10.2353/ajpath.2010.090750
Source: PubMed

ABSTRACT

Decreased blood flow to the brain in humans is associated with altered Alzheimer's disease (AD)-related pathology, although the underlying mechanisms by which hypoperfusion influences AD neuropathology remains unknown. To try to address this question, we developed an oligemic model of cerebral hypoperfusion in the 3xTg-AD mouse model of AD. We bilaterally and transiently occluded the common carotid artery and then examined the molecular and cellular pathways by which hypoperfusion influenced tau and amyloid-beta proteins. We report the novel finding that a single, mild, transient hypoperfusion insult acutely increases Abeta levels by enhancing beta-secretase protein expression. In contrast, transient hypoperfusion markedly decreases total tau levels, coincident with activation of macroautophagy and ubiquitin-proteosome pathways. Furthermore, we find that oligemia results in a significant increase specifically in tau phosphorylated at serine(212) and threonine(214), a tau epitope associated with paired helical filaments in AD patients. Despite the mild and transient nature of this hypoperfusion injury, the pattern of decreased total tau, altered phosphorylated tau, and increased amyloid-beta persisted for several weeks postoligemia. Our study indicates that a single, mild, cerebral hypoperfusion event produces profound and long lasting effects on both tau and amyloid-beta. This finding may have implications for the pathogenesis of AD, as it indicates for the first time that total tau and amyloid-beta are differentially impacted by mild hypoperfusion.

Download full-text

Full-text

Available from: Kim N Green, May 28, 2014
  • Source
    • "Following transfer, the membranes were blocked overnight in PBS with 1% bovine serum albumin and 2% BlockAce (AbD Serotec, Raleigh, NC, USA). Blots were then probed with AT8 (Greco et al., 2010;Koike et al., 2010;van Eersel et al., 2010;MartinezCoria et al., 2010a) for pSer202/pThr205 tau (Pierce; 1:500), AT180 (Koike et al., 2010;Martinez-Coria et al., 2010a) for pThr231 tau (Pierce, 1:100), PHF-1 (Martinez-Coria et al., 2010a) for pSer396/pS404 (courtesy of Dr. Peter Davies, Albert Einstein College of Medicine , Bronx, NY 1:1000), HT7 (Koike et al., 2010;van Eersel et al., 2010;Martinez-Coria et al., 2010a) for total tau (Pierce, 1:1000) which has been shown to detect both human and rodent total tau (Oddo et al., 2007;Resende et al., 2008;Ke et al., 2009;Martinez-Coria et al., 2010b), and anti-GAPDH (ab9385, Abcam; Cambridge, MA, USA, 1:5000) antibodies then probed with HRP-conjugated rabbit anti-mouse secondary antibody (Rockland Immunochemicals; Gilbertsville, PA, USA, 1:10,000). Membranes were then incubated with SuperSignal West Dura chemiluminescent substrate (Pierce), and exposed to film. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity and type 2 diabetes mellitus (T2DM) convey an increased risk for developing dementia. The microtubule associated protein tau is implicated in neurodegenerative disease by undergoing hyperphosphorylation and aggregation, leading to cytotoxicity and neurodegeneration. Enzymes involved in the regulation of tau phosphorylation, such as GSK3β, are tightly associated with pathways found to be dysregulated in T2DM. We have shown previously that leptin resistant mice, which develop obesity and a diabetic phenotype, display elevated levels of tau phosphorylation. Here we show cells cultured with leptin, an adipokine shown to have neuroprotective effects, reduces tau phosphorylation. To explore how this mechanism works in vivo we transduced an existing diabetic mouse line (Lepr(db/db)) with a tau mutant (tau(P301L)) via adeno-associated virus. The resulting phenotype included a striking increase in tau phosphorylation and the number of neurofibrillary tangles found within the hippocampus. We conclude that leptin resistance-induced obesity and diabetes accelerates the development of tau pathology. This model of metabolic dysfunction and tauopathy provides a new system in which to explore the mechanisms underlying the ways in which leptin resistance and diabetes influence development of tau pathology, and may ultimately be related to the development of neurofibrillary tangles.
    Full-text · Article · Dec 2015 · Neuroscience
  • Source
    • "Tau hyperphosphorylation and Ab overproduction appear to be very sensitive to cerebral hypoperfusion. Koike et al. have reported that a single, mild, cerebral hypoperfusion has profound and long lasting effects on tau hyperphosphorylation and Ab overproduction in 3xTg-AD mice (Koike et al. 2010). It is thus reasonable to speculate that repeated transient cerebral ischemia could contribute to the development of AD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic cerebral hypoperfusion (CCH) is a common consequence of various cerebral vascular disorders and hemodynamic and blood changes. Recent studies have revealed an important role of CCH in neurodegeneration and dementia, including vascular dementia and Alzheimer's disease (AD). This article reviews the recent advances in understanding CCH-induced neurodegeneration and AD-related brain pathology and cognitive impairment. We discuss the causes and assessment of CCH, the possible mechanisms by which CCH promotes Alzheimer-like pathology and neurodegeneration, and animal models of CCH. It appears that CCH promotes neurodegeneration and AD through multiple mechanisms, including induction of oxidative stress, Aβ accumulation and aggravation, tau hyperphosphorylation, synaptic dysfunction, neuronal loss, white matter lesion, and neuroinflammation. Better understanding of the mechanisms of CCH will help develop therapeutic strategies for preventing and treating neurodegeneration, including sporadic AD and vascular dementia, caused by CCH.
    Full-text · Article · Oct 2014 · Cellular and Molecular Neurobiology
  • Source
    • "so facilitate Ab production by activating the APP cleav - age enzyme b - secretase ( Kitaguchi et al . , 2009 ; Sun et al . , 2006 ; Tesco et al . , 2007 ; Wen et al . , 2004a ) . Cerebral ischemia promotes amyloid plaque formation ( Garcia - Alloza et al . , 2011 ; Kitaguchi et al . , 2009 ; Okamoto et al . , 2012 ) , and tau phos - phorylation ( Koike et al . , 2010 ; Wen et al . , 2007 ; 2004b ) . The vascular effects of Ab may also impair the clearance of the pep - tide , a key factor in brain Ab accumulation in sporadic AD ( Mawuenyega et al . , 2010 ) . The vascular pathway is estimated to be a major route of removal of Ab from the brain ( Castellano et al . , 2012 ; Shibata et al . , 2000 ) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vascular cognitive impairment defines alterations in cognition, ranging from subtle deficits to full-blown dementia, attributable to cerebrovascular causes. Often coexisting with Alzheimer's disease, mixed vascular and neurodegenerative dementia has emerged as the leading cause of age-related cognitive impairment. Central to the disease mechanism is the crucial role that cerebral blood vessels play in brain health, not only for the delivery of oxygen and nutrients, but also for the trophic signaling that inextricably links the well-being of neurons and glia to that of cerebrovascular cells. This review will examine how vascular damage disrupts these vital homeostatic interactions, focusing on the hemispheric white matter, a region at heightened risk for vascular damage, and on the interplay between vascular factors and Alzheimer's disease. Finally, preventative and therapeutic prospects will be examined, highlighting the importance of midlife vascular risk factor control in the prevention of late-life dementia.
    Full-text · Article · Nov 2013 · Neuron
Show more